> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Flip Flops; Agrees to Now Review Moderna Vaccine
- URL: https://www.fdaweb.com/fda-flip-flops-agrees-to-now-review-moderna-vaccine/
- Published: 2026-02-18T12:00:00.000Z
- Updated: 2026-09-14T13:34:00.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5160684

FDA has agreed to review Moderna’s seasonal influenza mRNA vaccine after previously refusing to file the BLA ([see earlier story](https://www.fdaweb.com/debate-intensifies-over-politicization-of-mrna-vaccines/)), a reversal that follows mounting scrutiny of the agency’s handling of mRNA products. The agency flip-flop followed what media reports describe as an unusual, high-level meeting between agency leadership and the vaccine maker.

According to multiple reports, senior FDA officials met directly with Moderna executives in a Type A meeting — a formal dispute-resolution mechanism typically used to address stalled applications. Several media outlets characterized the engagement as atypical both in timing and level of leadership involvement, suggesting the dispute escalated quickly inside the agency.

Following that meeting, Moderna proposed a revised regulatory pathway that splits the approval request by age cohort: full approval for adults ages 50 to 64 and accelerated approval for adults 65 and older, coupled with a post-marketing commitment to conduct an additional study in seniors. The agency has assigned a user fee review action target date of 8/5.

“We appreciate the FDA’s engagement in a constructive Type A meeting and its agreement to advance our application for review,” CEO **Stephane Bancel** said in a statement. If approved, mRNA-1010 would be available for adults 50 and older, including those 65 and above, in time for the 2026–2027 flu season.

The rapid pivot has fueled questions about internal deliberations at the agency and whether broader political and policy dynamics surrounding mRNA vaccines are influencing regulatory posture. Over the past year, mRNA-based products have faced heightened political scrutiny, and recent FDA decisions involving other vaccine applications have intensified debate over consistency in evidentiary standards.

Analysts quoted in today’s coverage noted that reversals of refusal-to-file decisions are rare. While Type A meetings can resolve scientific disagreements, it is uncommon for an application rejected at the filing stage to return to active review within days. The episode has raised concerns about regulatory predictability, particularly for sponsors relying on established surrogate endpoints in influenza vaccine development.